Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP01 inhaled pirfenidone access study for progressive fibrosing interstitial lung diseases
NL-OMON60760Phase 2Completed
- Sponsor
- Avalyn Pharmaceuticals
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pirfenidone in interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and 3 more, sponsored by Avalyn Pharmaceuticals. Started Jul 2021; status: completed.
02
Drugs
pirfenidone
03
Conditions
interstitial lung disease (ILD)idiopathic pulmonary fibrosis (IPF)progressive pulmonary fibrosis (PPF)pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD)
Beyond the preview
Go deeper on NL-OMON60760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60760.